SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
Trade name : Timolol / Dorzolamide Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
Use of the Substance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
Company : MSD
Piercetown
A86 HD21 Dunboyne, Ireland

Telephone : 908-740-4000
E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture
Classification (REGULATION (EC) No 1272/2008)
Specific target organ toxicity - repeated exposure, Category 1, Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs
H372: Causes damage to organs through prolonged or repeated exposure.

2.2 Label elements
Labelling (REGULATION (EC) No 1272/2008)
Hazard pictograms :
Signal word : Danger
Hazard statements : H372 Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.
Precautionary statements : Prevention:
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
Response:  
P314  Get medical advice/ attention if you feel unwell.

2.3 Other hazards  
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

SECTION 3: Composition/information on ingredients

3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No. EC-No. Index-No. Registration number</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dorzolamide</td>
<td>130693-82-2</td>
<td>Acute Tox. 4; H302 STOT RE 2; H373 (Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder)</td>
<td>(\geq 1 - &lt; 10)</td>
</tr>
<tr>
<td>(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate</td>
<td>26921-17-5 248-111-5</td>
<td>Acute Tox. 4; H302 Repr. 2; H361d STOT RE 1; H372 (Lungs, Cardiovascular system)</td>
<td>(\geq 0.1 - &lt; 1)</td>
</tr>
</tbody>
</table>

For explanation of abbreviations see section 16.

SECTION 4: First aid measures

4.1 Description of first aid measures  
General advice:  In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders:  First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
If inhaled

: If inhaled, remove to fresh air.
    Get medical attention.

In case of skin contact

: In case of contact, immediately flush skin with soap and plenty of water.
    Remove contaminated clothing and shoes.
    Get medical attention.
    Wash clothing before reuse.
    Thoroughly clean shoes before reuse.

In case of eye contact

: Flush eyes with water as a precaution.
    Get medical attention if irritation develops and persists.

If swallowed

: If swallowed, DO NOT induce vomiting.
    Get medical attention.
    Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks

: Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment

: Treat symptomatically and supportively.

SECTION 5: Firefighting measures

5.1 Extinguishing media

Suitable extinguishing media

: Water spray
    Alcohol-resistant foam
    Carbon dioxide (CO2)
    Dry chemical

Unsuitable extinguishing media

: None known.

5.2 Special hazards arising from the substance or mixture

Specific hazards during firefighting

: Exposure to combustion products may be a hazard to health.

Hazardous combustion products

: Carbon oxides
    Nitrogen oxides (NOx)
    Sulphur oxides
    Hydrogen chloride

5.3 Advice for firefighters

Special protective equipment for firefighters

: In the event of fire, wear self-contained breathing apparatus.
    Use personal protective equipment.

Specific extinguishing method

: Use extinguishing measures that are appropriate to local cir-
SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions:
- Use personal protective equipment.
- Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

Environmental precautions:
- Avoid release to the environment.
- Prevent further leakage or spillage if safe to do so.
- Prevent spreading over a wide area (e.g. by containment or oil barriers).
- Retain and dispose of contaminated wash water.
- Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

Methods for cleaning up:
- Soak up with inert absorbent material.
- For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container.
- Clean up remaining materials from spill with suitable absorbent.
- Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures:
- See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation:
- Use only with adequate ventilation.

Advice on safe handling:
- Do not breathe mist or vapours.
- Do not swallow.
- Avoid contact with eyes.
- Avoid prolonged or repeated contact with skin.
- Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment.

Do not eat, drink or smoke when using this product.

Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures:

- If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
- The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers:

- Keep in properly labelled containers. Store in accordance with the particular national regulations.

Advice on common storage:

- Do not store with the following product types:
  - Strong oxidizing agents
  - Organic peroxides
  - Explosives
  - Gases

7.3 Specific end use(s)

Specific use(s):

- No data available

SECTION 8: Exposure controls/personal protection

8.1 Control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dorzolamide</td>
<td>130693-82-2</td>
<td>TWA</td>
<td>10 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Eye</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
<tr>
<td>(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate</td>
<td>26921-17-5</td>
<td>TWA</td>
<td>10 µg/m3 (OEB 3)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Further information: Eye, Skin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>Wipe limit</td>
<td>100 µg/100 cm²</td>
<td>Internal</td>
</tr>
</tbody>
</table>
# SECTION 9: Physical and chemical properties

## 9.1 Information on basic physical and chemical properties

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical state</td>
<td>liquid</td>
</tr>
<tr>
<td>Colour</td>
<td>colourless</td>
</tr>
<tr>
<td>Odour</td>
<td>No data available</td>
</tr>
<tr>
<td>Odour Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>Melting point/freezing point</td>
<td>No data available</td>
</tr>
<tr>
<td>Initial boiling point and boiling</td>
<td>No data available</td>
</tr>
<tr>
<td>range</td>
<td></td>
</tr>
<tr>
<td>Flammability (solid, gas)</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Flammability (liquids)</td>
<td>No data available</td>
</tr>
<tr>
<td>Upper explosion limit / Upper</td>
<td>No data available</td>
</tr>
<tr>
<td>flammability limit</td>
<td></td>
</tr>
</tbody>
</table>
SECTION 10: Stability and reactivity

10.1 Reactivity
Not classified as a reactivity hazard.

10.2 Chemical stability
Stable under normal conditions.

10.3 Possibility of hazardous reactions
Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
Conditions to avoid: None known.

10.5 Incompatible materials
Materials to avoid: Oxidizing agents

10.6 Hazardous decomposition products
No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008
Information on likely routes of exposure:
- Inhalation
- Skin contact
- Ingestion
- Eye contact

Acute toxicity
Not classified based on available information.

Product:
Acute oral toxicity: Acute toxicity estimate: > 2,000 mg/kg
Method: Calculation method

Components:

Dorzolamide:
Acute oral toxicity: LD50 (Rat): 1,927 mg/kg
LD50 (Mouse): 1,320 mg/kg
Acute inhalation toxicity: Remarks: No data available
Acute dermal toxicity: Remarks: No data available

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Acute oral toxicity: LD50 (Rat): 1,000 mg/kg
LD50 (Mouse): 1,140 mg/kg
Acute toxicity (other routes of administration):
LD50 (Mouse): 300 mg/kg
Application Route: Intraperitoneal
LD50 (Mouse): 800 mg/kg
Application Route: Subcutaneous

Skin corrosion/irritation
Not classified based on available information.

Components:
(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Timolol / Dorzolamide Formulation

Species: Rabbit
Method: Draize Test
Result: No skin irritation

Serious eye damage/eye irritation
Not classified based on available information.

Components:

Dorzolamide:
Species: Monkey
Result: Mild eye irritation

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species: Rabbit
Result: Mild eye irritation

Species: Dog
Result: No eye irritation

Respiratory or skin sensitisation

Skin sensitisation
Not classified based on available information.

Respiratory sensitisation
Not classified based on available information.

Components:

Dorzolamide:
Test Type: Maximisation Test
Exposure routes: Skin contact
Species: Guinea pig
Result: Weak sensitizer

Germ cell mutagenicity
Not classified based on available information.

Components:

Dorzolamide:
Genotoxicity in vitro: Test Type: Chromosomal aberration
Result: negative

Test Type: Alkaline elution assay
Test system: rat hepatocytes
Result: negative

Test Type: In vitro mammalian cell gene mutation test
Test system: Chinese hamster fibroblasts
Result: negative
Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Genotoxicity in vivo  :  Test Type: Cytogenetic assay  
Species: Mouse  
Result: negative

(S)-3-[3-(tert-butyldimino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Genotoxicity in vitro  :  Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Genotoxicity in vivo  :  Test Type: In vivo micronucleus test  
Species: Mouse  
Method: OECD Test Guideline 474  
Result: negative

Carcinogenicity
Not classified based on available information.

Components:

Dorzolamide:
Species  :  Rat, male
Application Route  :  Oral
Exposure time  :  2 Years  
Result  :  20 mg/kg body weight  
Remarks  :  The mechanism or mode of action may not be relevant in humans.

Species  :  Mouse
Application Route  :  Oral
Exposure time  :  21 month(s)
Result  :  negative

(S)-3-[3-(tert-butyldimino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:

Species  :  Rat
Application Route  :  Oral
Exposure time  :  2 Years
LOAEL  :  300 mg/kg body weight
Result  :  negative
Target Organs  :  Adrenal gland
Remarks  :  The significance of these findings for humans is not certain.

Species  :  Mouse, female
Application Route  :  Oral
Exposure time  :  18 Months
LOAEL  :  500 mg/kg body weight
Result  :  negative
Target Organs  :  Lungs, Mammary gland, Uterus (including cervix)
Remarks  :  The significance of these findings for humans is not certain.
Carcinogenicity - Assessment: Weight of evidence does not support classification as a carcinogen

Reproductive toxicity
Not classified based on available information.

Components:

Dorzolamide:
Effects on fertility: Test Type: Fertility
Species: Rat, male and female
Application Route: Oral
Fertility: NOAEL: 7.5 mg/kg body weight
Result: Animal testing did not show any effects on fertility.

Effects on foetal development: Test Type: Development
Species: Rabbit
Application Route: Oral
Developmental Toxicity: NOAEL: 1 mg/kg body weight
Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Effects on fertility: Test Type: Fertility/early embryonic development
Species: Rat
Application Route: Oral
Fertility: NOAEL Mating/Fertility: 150 mg/kg body weight
Early Embryonic Development: NOAEL F1: 150 mg/kg body weight

Effects on foetal development: Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: LOAEL F1: 50 mg/kg body weight
Result: Some evidence of adverse effects on development, based on animal experiments.

Reproductive toxicity - Assessment: Some evidence of adverse effects on development, based on animal experiments.

STOT - single exposure
Not classified based on available information.
Timolol / Dorzolamide Formulation

STOT - repeated exposure
Causes damage to organs (Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs) through prolonged or repeated exposure.

Product:
Target Organs : Cardio-vascular system, Central nervous system, Gastrointestinal tract, Lungs
Assessment : Causes damage to organs through prolonged or repeated exposure.

Components:
Dorzolamide:
Target Organs : Central nervous system, Gastrointestinal tract, Bone, Blood, Bladder
Assessment : May cause damage to organs through prolonged or repeated exposure.

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Target Organs : Lungs, Cardio-vascular system
Assessment : Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity
Components:
Dorzolamide:
Species : Rat
NOAEL : 0.05 mg/kg
Application Route : Oral
Target Organs : Bladder, Kidney

Species : Dog
NOAEL : 0.05 mg/kg
LOAEL : 2 mg/kg
Application Route : Oral
Exposure time : 1 yr
Target Organs : Gastrointestinal tract, Bone, Blood

Species : Monkey
NOAEL : 0.05 mg/kg
Exposure time : 1 yr
Target Organs : Gastrointestinal tract, Bone, Blood

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
Species : Rat
NOAEL : 25 mg/kg
Application Route : Oral
Exposure time : 67 Weeks

Species : Dog
**NOAEL**

10 mg/kg

**Application Route**

Oral

**Exposure time**

54 Weeks

**Target Organs**

Kidney

**Aspiration toxicity**

Not classified based on available information.

### 11.2 Information on other hazards

**Endocrine disrupting properties**

**Product:**

**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

**Experience with human exposure**

**Product:**

**Eye contact:**

Symptoms: The most common side effects are: bitter taste, burning or stinging of the eye, Blurred vision, Abdominal pain, Dizziness, digestive disorder, eye pain, Headache, hypertension, Nausea, upper respiratory tract infection

**Components:**

**Dorzolamide:**

Eye contact: Symptoms: burning or stinging of the eye, Blurred vision, tearing, asthenia, bitter taste, Nausea, dry mouth, Headache

**(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:**

Eye contact: Symptoms: burning or stinging of the eye, dryness of the eyes, Headache, Nausea, Dizziness, dry mouth, changes in libido, hair loss, Allergic reactions

Ingestion: Symptoms: Headache, Fatigue, Respiratory disorders, Gastrointestinal discomfort, Allergic reactions, Rash, hair loss, altered mental status, Dizziness, changes in libido

### SECTION 12: Ecological information

#### 12.1 Toxicity

**Components:**

**Dorzolamide:**

Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): > 1,000 mg/l

Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 699 mg/l

Exposure time: 48 h
Timolol / Dorzolamide Formulation

Toxicity to microorganisms:
- EC50 (Natural microorganism): > 800 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- Method: OECD Test Guideline 209

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
- Toxicity to fish: LC50 (Pimephales promelas (fathead minnow)): 411 mg/l
- Exposure time: 96 h

- Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 161 mg/l
- Exposure time: 48 h
- Method: OECD Test Guideline 202

- Toxicity to microorganisms: EC50: > 1,000 mg/l
- Exposure time: 3 h
- Test Type: Respiration inhibition
- EC50 (Photobacterium phosphoreum): > 1,800 mg/l

12.2 Persistence and degradability

Components:

Dorzolamide:
- Biodegradability: Result: not rapidly degradable
- Biodegradation: 5 %
- Exposure time: 28 d
- Method: OECD Test Guideline 314

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
- Biodegradability: Result: Not readily biodegradable.
- Biodegradation: 0 %
- Exposure time: 30 d

Stability in water:
- Hydrolysis: 0 % (61 d)
- Method: FDA 3.09

12.3 Bioaccumulative potential

Components:

Dorzolamide:
- Partition coefficient: n-octanol/water: log Pow: 0.292

(S)-3-[3-(tert-butylamino)-2-hydroxypropoxy]-4-morpholino-1,2,5-thiadiazole monomaleate:
- Partition coefficient: n-octanol/water: log Pow: 1.48

12.4 Mobility in soil
- No data available
12.5 Results of PBT and vPvB assessment

**Product:**
**Assessment:** This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

12.6 Endocrine disrupting properties

**Product:**
**Assessment:** The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

12.7 Other adverse effects

No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods

**Product:** Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

**Contaminated packaging:** Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number or ID number

Not regulated as a dangerous good

14.2 UN proper shipping name

Not regulated as a dangerous good

14.3 Transport hazard class(es)

Not regulated as a dangerous good

14.4 Packing group

Not regulated as a dangerous good

14.5 Environmental hazards

Not regulated as a dangerous good

14.6 Special precautions for user

Not applicable

14.7 Maritime transport in bulk according to IMO instruments
Timolol / Dorzolamide Formulation

Version 3.11  Revision Date: 27.08.2021  SDS Number: 28809-00019  Date of last issue: 09.04.2021  Date of first issue: 06.11.2014

Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII):

- Conditions of restriction for the following entries should be considered: Number on list 3

REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59):

- Not applicable

Regulation (EC) No 1005/2009 on substances that deplete the ozone layer:

- Not applicable

Regulation (EU) 2019/1021 on persistent organic pollutants (recast):

- Not applicable

Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals:

- Not applicable

REACH - List of substances subject to authorisation (Annex XIV):

- Not applicable


- Not applicable

Other regulations:

Take note of Directive 94/33/EC on the protection of young people at work or stricter national regulations, where applicable.

The components of this product are reported in the following inventories:

- AICS: not determined
- DSL: not determined
- IECSC: not determined

15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information

Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements

- H302: Harmful if swallowed.
- H361d: Suspected of damaging the unborn child.
- H372: Causes damage to organs through prolonged or repeated exposure.
- H373: May cause damage to organs through prolonged or repeated exposure.

Full text of other abbreviations
Timolol / Dorzolamide Formulation

Acute Tox. : Acute toxicity
Repr. : Reproductive toxicity
STOT RE : Specific target organ toxicity - repeated exposure

Further information

Sources of key data used to compile the Safety Data Sheet:

Classification of the mixture:
STOT RE 1

Classification procedure:
Based on product data or assessment

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, disposal, storage, transportation, distribution and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their
intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.

IE / EN